DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for seborrheic dermatitis — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSeborrheic dermatitis maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for seborrheic dermatitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
kallikrein related peptidase 7 (KLK7) — KLK7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-carboxypropanoyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2QXI · 1.0 Å · ligand N-(3-carboxypropanoyl)-L-alanyl-L-alanyl-N-[(2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]-L-prolinamide (K7J). Experimental structure, not a prediction.
What the evidence adds up to
A 2025 synthesis of 41 clinical studies examined off-label and adjunctive therapies for seborrheic dermatitis. The table summarises each study’s design, sample size, treatment modality, disease subtype, therapy duration, and primary endpoints. Efficacy outcomes and adverse event profiles are reported alongside evidence levels I through IV, and key methodological limitations are noted. The same synthesis is presented in two identical entries.
A 2022 review describes seborrheic dermatitis as one of the most common dermatological conditions, affecting people regardless of geography or ethnicity. The review notes that the condition remains puzzling to dermatologists and patients because of its varying presentations and recurring nature. No specific drug, response rate, or survival data are reported in this review.
The 2025 synthesis does not provide individual numerical outcomes such as response rates or sample sizes for any single therapy. It does not name any specific drug. The evidence is stratified by level, but the actual results for each off-label or adjunctive intervention are not given in the abstracts provided. The 2022 review offers no quantitative efficacy data.
What is still missing from the available evidence is a clear, numerically detailed comparison of off-label therapies against standard first-line treatments. The 2025 synthesis acknowledges methodological limitations but does not specify what they are. No trial design improvements, patient stratification strategies, or funding sources are discussed in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Actas Dermo-Sifiliográficas · 2007 · 68 citations · open access
Clinical and Therapeutic Profile and Quality of Life of Patients With Seborrheic Dermatitis
AbstractThe clinical characteristics of seborrheic dermatitis (SD), therapeutic strategies employed in current clinical practice and impact on the quality of life in the Spanish population are described. An epidemiological, multicenter, transversal study in patients older than 16 years with seborrheic dermatitis. We evaluated the intensity of symptoms (scale 0-4), and impact on the quality of life by the Skindex-29 questionnaire (scale 0-100). Two thousand one hundred and fifty nine patients participated, the mean age was 43.6 years, 55% were men and 42% had a family history of seborrheic dermatitis. Diagnosis is usually carried out at a mean age of 33.7 years. The median number of outbreaks in the last year is three. The median duration of each outbreak is 14 days. The most involved areas are the face (88%) and scalp (70%). The mean intensities are as follows: scaling 1.9, erythema 1.89, pruritus 1.73, oily skin 1.52, and induration 0.87. Ninety-eight percent of patients report a trigger factor for outbreaks, namely stress/depression/fatigue (76%) and seasonal variation (44%). Acne is the most common concomitant disease (35%). The most common treatments are topical steroids (60%), imidazole antifungals (35%) and hydratating/nutritive products (31%). The mean Skindex-29 global score is 20.5. The most common clinical profile of seborrheic dermatitis is a 40-year-old patient with facial/scalp involvement of mild to moderate intensity with a history of stress/depression/fatigue prior to the outbreak. The most common treatments in the daily clinical practice are topical steroids and imidazole antifungals. The impact of seborrheic dermatitis in the quality of life is low. Se describen las características clínicas de la dermatitis seborreica (DS), las estrategias terapéuticas empleadas en la práctica clínica habitual y el impacto en la calidad de vida de la población afectada en España. Estudio epidemiológico, multicéntrico, transversal en pacientes mayores de 16 años con DS. Se evaluaron la intensidad de los síntomas (escala 0-4) y el impacto en la calidad de vida mediante el cuestionario Skindex-29 (escala 0-100). Participaron 2.159 pacientes, con una edad media de 43,6 años, el 55% hombres y el 42% con antecedentes familiares de DS. El diagnóstico se realizó como media a los 33,7 años. La mediana de brotes en el último año es de 3. La duración mediana de cada brote es de 14 días. Las zonas más afectadas son la facial (88%) y el cuero cabelludo (70%). Las medias de las intensidades son: descamación 1,9, eritema 1,89, prurito 1,73, piel grasa 1,52, infiltración 0,87. El 98% de los pacientes refiere un factor desencadenante de los brotes, estrés/depresión/fatiga (76%) y estacionalidad (44%). La patología concomitante más común es el acné (35%). Los tratamientos más frecuentes son corticoides tópicos (60%), antimicóticos imidazólicos (35%) e hidratantes/nutritivos (31%). La puntuación global media del Skindex-29 es de 20,5. El perfil clínico mayoritario de la DS es un paciente de 40 años, con afectación facial/cuero cabelludo, intensidad leve-moderada, padeciendo un episodio de estrés/depresión/fatiga previo al brote. Los tratamientos más frecuentes, en la práctica clínica habitual, son corticoides tópicos y antimicóticos imidazólicos. El impacto de la DS sobre la calidad de vida es bajo.
<b>Characteristics and Outcomes of Clinical Studies Evaluating Off-Label and Adjunctive Therapies in Seborrheic Dermatitis</b>
AbstractThis table provides a structured synthesis of 41 clinical studies investigating non-first-line therapies for seborrheic dermatitis across diverse intervention classes. Each entry includes study design, sample size, treatment modality, disease subtype, duration of therapy, and primary endpoints. Efficacy outcomes, adverse event profiles, and key methodological limitations are summarized alongside evidence stratification (Levels I–IV) to facilitate critical appraisal.
<b>Characteristics and Outcomes of Clinical Studies Evaluating Off-Label and Adjunctive Therapies in Seborrheic Dermatitis</b>
AbstractThis table provides a structured synthesis of 41 clinical studies investigating non-first-line therapies for seborrheic dermatitis across diverse intervention classes. Each entry includes study design, sample size, treatment modality, disease subtype, duration of therapy, and primary endpoints. Efficacy outcomes, adverse event profiles, and key methodological limitations are summarized alongside evidence stratification (Levels I–IV) to facilitate critical appraisal.
Seborrheic dermatitis and pityriasis sicca: A review
AbstractSeborrheic dermatitis (SD) is one of the most common dermatological conditions faced by the general population, regardless of geographic location and ethnicity. Given its widespread existence, it still remains puzzling for dermatologists and the affected individuals due to its varying presentations and recurring nature. We have presented a concise review of seborrheic dermatitis and pityriasis sicca.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
